HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
Posted by rob on October 31, 2009 under Uncategorized | 
Comments are off for this article
| Related Articles |
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
Expert Rev Vaccines. 2009 Nov;8(11):1513-26
Authors: Tosti G, di Pietro A, Ferrucci PF, Testori A
Heat-shock proteins are highly conserved, stress-induced proteins with chaperone function for trafficking and delivering peptides within the different compartments of the cell. Tumor-derived heat-shock protein-peptide complexes (HSPPCs) can be used for vaccination against malignancies. In particular, the HSPPC-96-based vaccine vitespen (formerly Oncophage) is the first autologous cancer vaccine made from individual patients’ tumors that has shown encouraging results in clinical trials. In Phase I and II clinical trials, this vaccine has shown activity on different malignancies, such as gastric cancer, colorectal cancer, pancreatic cancer, non-Hodgkin’s lymphoma and chronic myelogenous leukemia. In Phase III clinical trials in melanoma and kidney cancer, it demonstrated an excellent safety profile with almost no toxicity. Heat-shock protein-based vaccines can be considered as a novel therapeutic approach with a promising role in cancer management.
PMID: 19863242 [PubMed - in process]